Anti-fibrotic activity of SCGB3A2 was demonstrated using bleomycin (BLM)-induced pulmonary fibrosis mouse model, in conjunction with intravenous administration of SCGB3A2 [17,18]. The gene discussed is SCGB3A2; the disease is pulmonary fibrosis.